Exendin-4 and Exenatide: The Gila Monster Peptide Behind the First GLP-1 Drug
Peptide drugs from venom
Exendin-4 is a 39-amino-acid peptide first isolated from Gila monster venom in 1992, and its synthetic form, exenatide, became the first GLP-1 receptor agonist approved in the United States. This article covers its discovery, why it outlasts native GLP-1, the trial results, the label warnings and what happened to the products.
What is exendin-4?
Exendin-4 is a 39-amino-acid peptide isolated from the venom of the Gila monster, Heloderma suspectum. The 1992 Journal of Biological Chemistry paper that reported its isolation describes it as an analogue of exendin-3, a related peptide from another lizard’s venom, and found that exendin-4 raised cAMP in guinea pig pancreatic acini through the exendin receptor, an effect blocked by exendin-(9-39). The synthetic version, exenatide, was the first GLP-1 receptor agonist sold in the United States: the Byetta label lists initial US approval in 2005.
It belongs to the group of venom-derived peptide drugs, and it is a good case study in how a natural peptide with the right receptor target can become a medicine.
How exendin-4 is studied to work
Both the Byetta and Bydureon labels describe exenatide as a GLP-1 receptor agonist, meaning it activates the receptor for the gut hormone covered in what is GLP-1. Native GLP-1 is cut quickly by the enzyme DPP-4, and an educational summary from RCSB PDB-101 puts its plasma half-life at under 2 minutes. The same summary reports that exendin-4 shares about 53 percent sequence identity with human GLP-1 and that several amino-acid differences make it a poor DPP-4 substrate. The Byetta label gives a mean terminal half-life of about 2.4 hours and says clearance is mainly by glomerular filtration plus proteolytic degradation.
That stability gap is a recurring theme; see peptide half-life explained and half-life extension strategies for the engineering approaches used by later drugs.
What the exenatide trials reported
A review of the three 30-week placebo-controlled phase III trials of twice-daily exenatide (add-on to metformin, a sulfonylurea, or both; 336, 377 and 773 participants) reported significant reductions in HbA1c in all three, with p less than 0.001. A later randomized, open-label, 30-week trial, DURATION-1, compared once-weekly with twice-daily exenatide in 295 adults with type 2 diabetes; HbA1c fell 1.9 percent with the weekly form and 1.5 percent with the twice-daily form (p = 0.0023), with no increased risk of hypoglycaemia and similar weight reductions.
Label safety points
Both labels report acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, with instructions to discontinue if it is suspected. The extended-release Bydureon BCise label carries a boxed warning: extended-release exenatide caused an increased incidence of thyroid C-cell tumors in rats at clinically relevant exposures, and it is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Nausea is the most common adverse reaction on the Byetta label; placebo-controlled rates ranged from 8 percent versus 0 percent in monotherapy to 44 percent versus 18 percent as add-on to metformin and/or a sulfonylurea, and the label says it is dose-related and often decreases over time. A pulmonary aspiration warning during anesthesia or deep sedation was added to both labels in November 2024. For the wider class, see GLP-1 side effects.
Availability today
A UnitedHealthcare provider notice dated December 19, 2024 says Byetta was discontinued on October 25, 2024 and Bydureon BCise on October 28, 2024, and that AstraZeneca notified the FDA; the notice gave no reason. The original Bydureon was reported by trade press as approved in 2012. Because the products are no longer marketed in the US, this article uses the past tense.
Research handling and unit context
Exenatide was supplied as finished injectable products, so it is not a reconstitution example for research powders. General unit arithmetic is in the reconstitution calculator and concentration converter; they are lab-math tools, not dosing guidance.
Frequently asked questions
Is exenatide the same as semaglutide?
No. Both activate the GLP-1 receptor, but exenatide is the synthetic form of a Gila monster venom peptide, while semaglutide is a modified human GLP-1 analogue.
Why does exendin-4 last longer than GLP-1?
It is a poor substrate for DPP-4, the enzyme that rapidly inactivates native GLP-1.
Did exendin-4 win a Nobel Prize?
No sourced claim of that kind was found, so none is made here.
Is exenatide still sold in the US?
According to the UnitedHealthcare notice cited below, Byetta and Bydureon BCise were discontinued in October 2024.
References
- Eng J et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 1992;267:7402-5.
- Exenatide once weekly versus twice daily for type 2 diabetes (DURATION-1). Lancet 2008;372:1240-50.
- Bond A. Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus. Proc (Bayl Univ Med Cent) 2006;19:281-4.
- Bydureon BCise (exenatide extended-release) FDA label, 2025.
- Byetta (exenatide) prescribing information (label text).
- RCSB PDB-101. Exenatide (educational summary).
- UnitedHealthcare provider notice, December 2024: discontinuation of Bydureon BCise and Byetta.
Informational only — not medical advice. This article is for educational purposes. It does not recommend, sell or instruct personal human use of any compound. Consult a qualified healthcare professional for any health decision. Content is intended for adults 21+. Verify scientific details against the primary sources cited.